Swissmedic’s Post

📢 The HAG welcomes the adoption by the European Commission of two critical implementing regulations concerning the rules for cooperation with the European Medicines Agency (EMA) for joint productions under the Health Technology Assessment Regulation (HTAR), as well as the management of conflicts of interest. 💡 These developments represent tangible steps toward the operationalization of a unified European HTA system. The HAG reaffirms its steadfast commitment to the implementation of the HTA Regulation and will continue to actively engage in this critical process. 💬 "Our shared vision is to establish a European HTA system that embodies the values of solidarity, inclusiveness, transparency, and impartiality, ultimately benefiting patients and healthcare systems across the EU." 👉 Read the full statement here: https://lnkd.in/d8YFsw5b #HTAR Rui Santos Ivo Agneta Karlsson Lionel Collet Niklas Hedberg Johan Pontén Judith Fernandez Maggie Galbraith Tiago Rodrigues Mariane Cossito Luis Vitor Gonzaga Silva Kieran Walsh Katrine Heier

🩺 Tomorrow the Dutch Parliament will debate the Dutch Global Health Strategy. This strategy is the cornerstone of the Netherlands’ approach to global public health challenges. We, the Dutch Global Health Alliance, have been closely monitoring the development of this strategy. As a coalition of 20 civil society organizations, we call on the Dutch Parliament to fully endorse the strategy and give it the political and financial support it needs. We share several key asks and recommendations to strengthen the strategy: Increase non-Official Development Assistance contributions to the strategy. Develop a comprehensive implementation agenda with clear measurable qualitative and quantitative indicators. Put stringent conditions on government funding for pharmaceutical research, ensuring transparency and affordability. Ensure that public-private partnerships in healthcare are accompanied by robust regulations that safeguard equity and prioritize the achievement of Sustainable Development Goal 3 on health.  🔗 Read our full position article here https://bit.ly/3VIvn5y  #GlobalHealth #HealthForAll #DutchGlobalHealthAlliance

🩺 Today the Dutch Parliament will debate the Dutch Global Health Strategy. This strategy is the cornerstone of the Netherlands’ approach to global public health challenges. We, the Dutch Global Health Alliance, have been closely monitoring the development of this strategy. As a coalition of 20 civil society organizations, we call on the Dutch Parliament to fully endorse the strategy and give it the political and financial support it needs. We share several key asks and recommendations to strengthen the strategy: Increase non-Official Development Assistance contributions to the strategy. Develop a comprehensive implementation agenda with clear measurable qualitative and quantitative indicators. Put stringent conditions on government funding for pharmaceutical research, ensuring transparency and affordability. Ensure that public-private partnerships in healthcare are accompanied by robust regulations that safeguard equity and prioritize the achievement of Sustainable Development Goal 3 on health.  🔗 Read our full position article here https://bit.ly/3VIvn5y   #GlobalHealth #HealthForAll #DutchGlobalHealthAlliance

🤝 In the last two days EAHP President-elect Nenad Miljković participated in the launch of the Critical Medicines Alliance. EAHP was the first European healthcare professionals organisation analysing the issue of medicines shortage, more than ten years ago. 💡 This Alliance constitutes a step forward in addressing medicines shortage and patients needs. EAHP is ready to get involved and will make all possible efforts to ensure a fruitful collaboration with the other interested parties in the interest of patients and public health. #EU2024BE #EAHP #CriticalMedicinesAlliance Belgian Presidency of the Council of the European Union 2024

🚀 Embracing open strategic autonomy, competitiveness in Europe will fuel better healthcare for all, #LevellingUp innovation, access, and independence. A Critical Medicines Act should be adopted in the first 100 days of office of the new European Commission.

🩺 Tomorrow the Dutch Parliament will debate the Dutch Global Health Strategy. This strategy is the cornerstone of the Netherlands’ approach to global public health challenges. We, the Dutch Global Health Alliance, have been closely monitoring the development of this strategy. As a coalition of 20 civil society organizations, we call on the Dutch Parliament to fully endorse the strategy and give it the political and financial support it needs. We share several key asks and recommendations to strengthen the strategy: Increase non-Official Development Assistance contributions to the strategy. Develop a comprehensive implementation agenda with clear measurable qualitative and quantitative indicators. Put stringent conditions on government funding for pharmaceutical research, ensuring transparency and affordability. Ensure that public-private partnerships in healthcare are accompanied by robust regulations that safeguard equity and prioritize the achievement of Sustainable Development Goal 3 on health. 🔗 Read our full position article here https://bit.ly/3VIvn5y

🩺 Today the Dutch Parliament will debate the Dutch Global Health Strategy. This strategy is the cornerstone of the Netherlands’ approach to global public health challenges. We, the Dutch Global Health Alliance, have been closely monitoring the development of this strategy. As a coalition of 20 civil society organisations, we call on the Dutch Parliament to fully endorse the strategy and give it the political and financial support it needs. We share several key asks and recommendations to strengthen the strategy: 1) Increase non-Official Development Assistance contributions to the strategy. 2) Develop a comprehensive implementation agenda with clear measurable qualitative and quantitative indicators. 3) Put stringent conditions on government funding for pharmaceutical research, ensuring transparency and affordability. 4) Ensure that public-private partnerships in healthcare are accompanied by robust regulations that safeguard equity and prioritize the achievement of Sustainable Development Goal 3 on health. 🔗 Read our full position article here https://bit.ly/3VIvn5y  #GlobalHealth #HealthForAll #DutchGlobalHealthAlliance

Ensuring uninterrupted access to essential medicines for all EU citizens is of utmost importance. Poland, like other EU Member States, faces medicine shortages, a challenge exacerbated by the COVID-19 pandemic. To solve the issue, the EU authorities have put this topic high on the priority agenda. The importance of the Critical Medicines Act, which aims to reduce dependencies on critical medicines and their ingredients, has also been emphasized in the European Commission's Political Guidelines for 2024-2029. Earlier, to better tackle medicine shortages, the Critical Medicines Alliance (CMA) was established in January 2024. CMA is a consultative platform that brings together key stakeholders from Member States, relevant industries, civil society representatives, and academia. Given these important developments, we are extremely enthused to announce that recently the Institute for Social Policy Development (IRSS) has officially joined the Critical Medicines Alliance (CMA), marking another important achievement and embarking on a new level of cooperation.   Throughout our various initiatives, expert workshops, and conferences dedicated to shaping healthcare policy in Poland and the EU, we have been consistently raising this issue not only from the Polish   perspective but also from the European one. We believe that Poland possesses the untapped potential to positively influence European medicine safety. We are pleased that the Polish government has also joined the Alliance, underscoring its dedication to addressing critical healthcare needs. Stay tuned for more updates as we start working on this incredible initiative. pl: https://lnkd.in/dhwHtNmH #IRSS #HealthcareForAll #CriticalMedicinesAlliance #SupplyChain #PublicHealth

🩺 Tomorrow the Dutch Parliament will debate the Dutch Global Health Strategy. This strategy is the cornerstone of the Netherlands’ approach to global public health challenges. We, the Dutch Global Health Alliance, have been closely monitoring the development of this strategy. As a coalition of 20 civil society organizations, we call on the Dutch Parliament to fully endorse the strategy and give it the political and financial support it needs. We share several key asks and recommendations to strengthen the strategy: 1️⃣ Increase non-Official Development Assistance contributions to the strategy. 2️⃣ Develop a comprehensive implementation agenda with clear measurable qualitative and quantitative indicators. 3️⃣ Put stringent conditions on government funding for pharmaceutical research, ensuring transparency and affordability. 4️⃣ Ensure that public-private partnerships in healthcare are accompanied by robust regulations that safeguard equity and prioritize the achievement of Sustainable Development Goal 3 on health.   🔗 Read our full position article here: https://lnkd.in/ewbDAE3e #GlobalHealth #HealthForAll #DutchGlobalHealthAlliance

RDI CEO Alexandra Heumber Perry gave a keynote address today at World Orphan Drug Congress USA, highlighting three main points: 1. The critical need to connect national, regional and global efforts: Health equity cannot be achieved in isolation - it requires a coordinated approach that transcends geographical boundaries 2. The key success of a multi-stakeholder approach: We must harness the collective expertise, resources and influence of governments, healthcare providers, industry stakeholds, advocacy groups and, most importantly, patients and their families. 3. the imperative for innovative solutions in healthcare financing for rare diseases: Traditional funding mechanisms often fall short in meeting the unique needs of individuals with rare conditions. High costs, limited market size and uncertain outcomes pose significant challenges. By embracing novel approaches such as value-based pricing, risk-sharing agreements, and innovate reimbursement models, we can ensure that cost is not a barrier to access. It's time to harness the power of collaboration, innovation and advocacy to build a world where every person living with a #raredisease has the opportunity to live a full and healthy life.